269 related articles for article (PubMed ID: 35343573)
1. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.
Balasubramanian A; John T; Asselin-Labat ML
Biochem Soc Trans; 2022 Apr; 50(2):825-837. PubMed ID: 35343573
[TBL] [Abstract][Full Text] [Related]
2. Antigen processing and immune regulation in the response to tumours.
Reeves E; James E
Immunology; 2017 Jan; 150(1):16-24. PubMed ID: 27658710
[TBL] [Abstract][Full Text] [Related]
3. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
4. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
6. Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.
Knittel D; Gadzinski A; Hua S; Denizeau J; Savatier A; de la Rochère P; Boulain JC; Amigorena S; Piaggio E; Sedlik C; Léonetti M
Vaccine; 2016 Jun; 34(27):3093-3101. PubMed ID: 27154391
[TBL] [Abstract][Full Text] [Related]
7. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
8. MHC-II neoantigens shape tumour immunity and response to immunotherapy.
Alspach E; Lussier DM; Miceli AP; Kizhvatov I; DuPage M; Luoma AM; Meng W; Lichti CF; Esaulova E; Vomund AN; Runci D; Ward JP; Gubin MM; Medrano RFV; Arthur CD; White JM; Sheehan KCF; Chen A; Wucherpfennig KW; Jacks T; Unanue ER; Artyomov MN; Schreiber RD
Nature; 2019 Oct; 574(7780):696-701. PubMed ID: 31645760
[TBL] [Abstract][Full Text] [Related]
9. MHC class I down-regulation: tumour escape from immune surveillance? (review).
Bubeník J
Int J Oncol; 2004 Aug; 25(2):487-91. PubMed ID: 15254748
[TBL] [Abstract][Full Text] [Related]
10. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
11. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
12. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
13. Autophagy proteins influence endocytosis for MHC restricted antigen presentation.
Münz C
Semin Cancer Biol; 2020 Nov; 66():110-115. PubMed ID: 30928540
[TBL] [Abstract][Full Text] [Related]
14. An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.
Olsson N; Heberling ML; Zhang L; Jhunjhunwala S; Phung QT; Lin S; Anania VG; Lill JR; Elias JE
Front Immunol; 2021; 12():662443. PubMed ID: 33936100
[TBL] [Abstract][Full Text] [Related]
15. Autophagy Beyond Intracellular MHC Class II Antigen Presentation.
Münz C
Trends Immunol; 2016 Nov; 37(11):755-763. PubMed ID: 27667710
[TBL] [Abstract][Full Text] [Related]
16. Mouse Norovirus Infection Reduces the Surface Expression of Major Histocompatibility Complex Class I Proteins and Inhibits CD8
Fritzlar S; Jegaskanda S; Aktepe TE; Prier JE; Holz LE; White PA; Mackenzie JM
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976673
[TBL] [Abstract][Full Text] [Related]
17. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
18. Autophagy and antigen presentation.
Münz C
Cell Microbiol; 2006 Jun; 8(6):891-8. PubMed ID: 16681832
[TBL] [Abstract][Full Text] [Related]
19. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.
Dersh D; Hollý J; Yewdell JW
Nat Rev Immunol; 2021 Feb; 21(2):116-128. PubMed ID: 32820267
[TBL] [Abstract][Full Text] [Related]
20. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
